Login
$SPRY
$3.59 -$0.30 (7.71%) Live

$SPRY 8-K SEC Filings

Filed On Filing
05 Nov 2026 8-K: Results of Operations and Financial Condition

Total Q3 revenue of $37.7 million, including $33.4 million in U.S. net product revenue for neffy®

13 Aug 2026 8-K: Results of Operations and Financial Condition

ARS Pharmaceuticals Outlines Strategic Priorities, including a Focused Commercial Strategy, and Reports Second Quarter 2026 Financial Results

17 Jul 2026 8-K: Departure/Election of Directors or Officers; Compensation

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

07 Jul 2026 8-K: Departure/Election of Directors or Officers; Compensation

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

25 Jun 2026 8-K: Submission of Matters to a Vote of Security Holders

On June 24, 2026, ARS Pharmaceuticals, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). As of April 27, 2026, the record date for the Annual Meeting, 99,300,658 shares of common stock were outstan...

15 May 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

Q1 2026 total revenue of $22.7 million including neffy U.S. net product revenue of $17.5 million

13 May 2026 8-K: Departure/Election of Directors or Officers; Compensation

This Executive Employment Agreement (this “Agreement”) is made and entered into effective as of May 12, 2026 (the “Effective Date”), by and between Donn Casale (“Executive”) and ARS Pharmaceuticals, Inc. (the “Company”).

09 Mar 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Updates on neffy® (epinephrine nasal spray) Commercialization

10 Nov 2025 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

$32.5 million in revenue, including $31.3 million in neffy U.S. net product revenue in third quarter of 2025

29 Sep 2025 8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation

CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY [***], HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE THE REGISTRANT HAS DETERMINED THE INFORMATION IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFI...

28 Aug 2025 8-K: Other Events

On August 13, 2025, ARS Pharmaceuticals, Inc. (the “Company”) received a Paragraph IV certification notice (the “Notice”) from Lupin Inc. (“Lupin”), advising that Lupin has submitted to the U.S. Food and Drug Administration (the “FDA”) a...

13 Aug 2025 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

ARS Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Accelerating Growth for neffy® (epinephrine nasal spray)

26 Jun 2025 8-K: Submission of Matters to a Vote of Security Holders

On June 25, 2025, ARS Pharmaceuticals, Inc. (the “Company”) held its 2025 Annual Meeting of Stockholders (the “Annual Meeting”). As of April 28, 2025, the record date for the Annual Meeting, 98,210,512 shares of common stock were outstan...

14 May 2025 8-K: Results of Operations and Financial Condition

ARS Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Progress in U.S. Commercial Launch of neffy® (epinephrine nasal spray)

02 May 2025 8-K: Entry into a Material Definitive Agreement

On May 2, 2025, ARS Pharmaceuticals, Inc. (“ARS”), through its wholly owned subsidiary ARS Pharmaceuticals Operations, Inc. (the “Company”), and ALK-Abelló, Inc. (“ALK”) entered into a co-promotion agreement (the “Co-Promotion Agreement”...

20 Mar 2025 8-K: Results of Operations and Financial Condition

$7.3 million in total neffy® (epinephrine nasal spray) U.S. net product revenue in 2024 since launch in late September 2024

05 Mar 2025 8-K: Other Events

On March 5, 2025, ARS Pharmaceuticals, Inc. (the “Company”) announced that the U.S. Food and Drug Administration (“FDA”) approved neffy 1 mg (epinephrine nasal spray) for the emergency treatment of allergic reactions (Type I), including ...

13 Jan 2025 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

Preliminary fourth quarter neffy® net product revenue of approximately $6.5 million

13 Nov 2024 8-K: Results of Operations and Financial Condition

Commercial launch of neffy® (epinephrine nasal spray) underway in the United States

12 Nov 2024 8-K: Entry into a Material Definitive Agreement

On November 9, 2024, ARS Pharmaceuticals, Inc. (“ARS”), through its wholly owned subsidiary ARS Pharmaceuticals Operations, Inc. (the “Company”), entered into a collaboration, license and distribution agreement (the “Collaboration Agreem...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support